The company was founded in Shenzhen in 1998 and is a leading multinational pharmaceutical company with an A+H dual financing platform. The company's three business segments collaborate with each other, driven by unmet clinical needs, and are committed to providing high-quality, safe and effective drugs and services to patients around the world to protect their health. The main business covers the heparin industry chain, the investment, development and commercialization of biomacromolecular CDMOs, and innovative drugs. We are committed to bringing high-quality safe and effective drugs and services to patients around the world to protect their health. Major products and services include enoxaparin sodium preparations, heparin sodium and enoxaparin sodium raw materials, and CDMO services for macromolecular drugs. Corporate honors: It has successively undertaken national science and technology projects such as the National Biotech Industrialization Demonstration Project, the National Torch Program Project, and the National Key Technological Innovation Project, and has made important contributions to the technological progress, industrial upgrading, and export foreign exchange generation capacity of China's heparin industry. The company has successively won the “National Technological Innovation Outstanding New Product Award”, “Shenzhen Excellent Private Enterprise”, “Shenzhen Excellent Private Enterprise”, “Shenzhen Youqiang Small and Medium Enterprise”, etc., and has become a key high-tech enterprise in the country and Shenzhen.
No Data